The global scleroderma therapeutics market is projected to grow at a considerable CAGR of around 4% during the forecast period (2020-2026). Scleroderma is a chronic autoimmune disease that results in chronic hardening and tightening of the skin and connective tissues. This disease is more common in females compared to males and is likely to develop at the age of 30-50 years. The rising female geriatric population along with the rising prevalence of scleroderma therapeutics to be a key contributor to the growth of the market across the globe. 

The advent of new first-in-class therapeutic that are currently undergoing clinical development and trial therapeutics. For instance, in March 2020, Emerald Health Pharmaceuticals Inc., a clinical-stage biotechnology company that develops drugs and medicines based on cannabinoid science, has initiated a Phase 2a international clinical study for the treatment of patients with systemic sclerosis (SSc), a severely debilitating and life-threatening form of scleroderma. 

Furthermore, the presence of increasing approvals for the existing treatment options to further anticipated boosting the market growth of scleroderma therapeutics across the globe. The ongoing R&D by the major market players to find out new novel therapies for the treatment of the disease is anticipated to offer huge opportunities to the growth of the global market. However, stringent rules and regulations, high costs associated with the therapies, and the adverse effects of drugs are the key factors that may restrain the growth of the global scleroderma therapeutics market.

Segmental Outlook  

The scleroderma therapeutics market is segmented on the basis of drug type and disease type. Based on the drug type, the market into Phosphodiesterase 5 inhibitors – PHA, prostacyclin analogues, immunosuppressors, endothelin receptor antagonists, calcium channel blockers, and others. Based on disease type, the market is segmented into systematic scleroderma and localized scleroderma. Systematic scleroderma is anticipated to hold major market share based on disease. Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs. The increasing prevalence of this disease is anticipated to drive the growth of this market segment. 

Immunosuppressants to be considerable segment based on Drug Type

Immunosuppressants are anticipated to register high growth based on drug type owing to the high intake of these drugs to get relief in scleroderma. The high price of immunosuppressants that are mainly used in the treatment of these diseases is a key factor contributing to the high share of the market segment. Although, these drugs are not FDA approved for the treatment of scleroderma several clinical trials are being done in progress to investigate the efficacy of immunosuppressants. The approval for its use in the treatment of scleroderma is anticipated to offer opportunities to the growth of this market segment.

Global Scleroderma Therapeutics Market Share by Drug Type, 2019 (%)

Regional Outlook 

The global scleroderma therapeutics market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a major market share in the global market. High healthcare expenditure, increasing investment in the R&D of novel therapies for the treatment of scleroderma, along with the presence of a huge patient pool in the region are the key factors that are making a huge contribution towards the high share of the scleroderma therapeutic in the region. The presence of proper medical reimbursement policies is further anticipated to boost the growth of the regional market.

Global Scleroderma Therapeutics Market Growth, by Region 2020-2026

Asia-Pacific to exhibit considerable growth during the forecast period 2020-2026

Asia-Pacific is anticipated to showcase considerable growth in the global scleroderma therapeutic market. The rising incidence and prevalence of scleroderma in the region along with the growth awareness among population related to its available treatment option is expected to be a key factor contributing to the growth of the regional market growth. Apart from this, increase in the number of R&D clinical trial to discover new therapies for its treatment is again driving the growth of the scleroderma therapeutics market in the Asia-Pacific region. However, the lack of awareness related to the available treatment option for scleroderma in the under-developed economies of the region is anticipated o restrain the market growth in the region. 

Market Players Outlook

Boehringer Ingelheim International GmbH, Celgene Corp., arGentis Pharmaceuticals, LLC, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals, Inc., Cytori Therapeutics Inc., Corbus Pharmaceuticals Holdings, Inc., Bayer AG, F. Hoffmann La-Roche Ltd., Bristol-Myers Squibb Company, and so on are the key companies operating in the scleroderma therapeutics market across the globe. The continuous efforts of the market players in development of new drugs are driving the growth of the global market.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global scleroderma therapeutics market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.